Onderzoeksgraad Solanezumab

SolanezumabisahumanizedmonoclonalIgG1antibodydirectedagainstthemid-domainoftheAβpeptide.Itrecognizessolublemonomeric, notfibrillar, Aβ.Solanezumab (formerlyknownasLY2062430) isamonoclonalantibodybeingdevelopedbyLillyasapotentialtherapyforpeoplewithmildcognitiveimpairmentcausedbyAlzheimer’sdisease.

LY2062430, CAS:955085-14-0

Mammalian Cells

AICD-57, A4, Beta-CTF, Proteasenexin-II, Gamma-CTF (50), ABPP, S-APP-beta, APP, Abeta40, Abeta42, AID (59), Amyloidintracellulardomain59, AID (57), S-APP-alpha, Gamma-CTF (59), Beta-secretaseC-terminalfragment, Amyloid-betaprecursorprotein, Amyloidprecursorprotein, Beta-APP42, PreA4, Alzheimerdiseaseamyloidprotein, APPI, PN-II, AICD-59, Alpha-secretaseC-terminalfragment, Amyloid-betaA4protein, Amyloidintracellulardomain57, CVAP, Amyloidintracellulardomain50, Beta-APP40, AD1, Cerebralvascularamyloidpeptide, AID (50), Alpha-CTF, Gamma-CTF (57), AICD-50

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Protein A/G purified from cell culture supernatant.

1.8mg/ml

Please contact with the lab for this information.

>95% as determined by SDS-PAGE.

Liquid

0.01M PBS, pH7.4.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at4°C short term (1-2weeks) . Store at-20°C 12 months. Store at -416°C long term.

For research use only. Not suitable for clinical or therapeutic use.

0.01M PBS, pH7.4.

Human

IgG1-kappa